PerindoprilatPerindoprilat
MedChemExpress (MCE)
HY-B1433
95153-31-4
S 9780
99.60%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research.
Perindoprilat (1 μM, 10 days) treatment suppresses the angiotensin II production in HNSCC cells[2]. Perindoprilat (40 μM, 3 days) treatment attenuates mesangial cell fibronectin level[3].
Perindoprilat (oral gavage
1.5 mg/kg
once daily
7 d) treatment improves cardiac function in mice with acute myocardial infarction and reduces the number of apoptotic myocardial cells[4]. Perindoprilat (oral gavage
1.5 mg/kg
once daily
7 d) treatment reduces the expression levels of myocardial Bax and Bcl-2 in infarction zones of mice with acute myocardial infarction[4]. Perindoprilat (oral gavage
1.5 mg/kg
once daily
7 d) treatment lowers the expression of myocardial TLR4/NF-κB in infarction zones in mice with acute myocardial infarction[4].
| | | |
| | | | | |
[1]. Perindopril. Expert Opin Pharmacother. 2006 Jan
7(1):63-71. [Content Brief]
[2]. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22
577(1-3):1-6. [Content Brief]
[3]. Izabella Z A Pawluczyk, et al. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Kidney Int. 2004 Apr
65(4):1240-51. [Content Brief]
[4]. X-Z Wang, et al. Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway. Eur Rev Med Pharmacol Sci. 2019 Aug
23(15):6672-6682. [Content Brief]